BNOX bionomics.com.au Net earnings per share for the last 12 months

The annual EPS TTM snapshot demonstrates the financial dynamics of Bionomics Limited (BNOX), where the metric stands at -0.94. The company's Australian centers are developing innovative antidepressants, leveraging progress in clinical trials. Diversification of the small-molecule CNS portfolio mitigates investment risks, while strict FDA protocols protect the technological ecosystem, attracting new R&D partners.

BNOX Bionomics Limited Earnings per share for the trailing year (07/04/2022 - 12/24/2024)

Bionomics Limited - analytical breakdowns and key metrics (BNOX)

- stock price and consensus target price:

Stock Price Bionomics Ltd|BNOX - Average Forecast Price

- market capitalization data:

Market Valuation Bionomics Ltd.|BNOX - Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Bionomics|BNOX - Accounting Value of Company|Market Value to Book Value Ratio bionomics.com.au|BNOX - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

BNOX - Company Net Income|Projected Future Earnings Bionomics Limited|BNOX - Business Payback Period|Future Price to Earnings Bionomics Ltd|BNOX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionomics|BNOX - Operating profit before amortization|Earnings per share for the last twelve months Bionomics|BNOX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bionomics.com.au|BNOX - Net earnings per share growth this year|Earnings growth forecast for next year Bionomics Limited

- issuer revenue and sales details:

BNOX - Company Gross Revenue|Projected Sales Volume Bionomics|BNOX - Market Cap to Revenue|Price-to-Projected Revenue Ratio Bionomics

Basic company analysis:Bionomics Ltd. (BNOX)

Bionomics Limited focuses on developing PTSD treatments, where the primary expenses are allocated to R&D. This indicator calculates the total annual income per share, neutralizing the volatility of short-term reports. Investors use it to assess the impact of operating expenses on capitalization. For biotech companies, negative values are expected until clinical phases are completed. By analyzing the annual net income per share chart, one can track the capital burn rate.

Analysis of competing companies